LEADER: Liraglutide Effect and Action in Diabetes Evaluation of cardiovascular outcome Results
The purpose of this clinical research trial is to determine the effect of liraglutide on heart or blood vessels in people with type 2 diabetes. Liraglutide is a once-daily GLP-1 (glucagon-like peptide-1) analogue, which is administered by subcutaneous injection. Liraglutide has been shown to reduce the effects of hyperglycemia, insulin resistance, high cholesterol, hypertension and obesity. Patients will be compensated for their time and travel expenses.
You may be eligible to participate in this study if you:
- Have type 2 diabetes
- Are > 50 years of age at screening and have concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or CHF -OR- age > 60 years at screening and other specified risk factors of vascular disease
- Have a HbA1c > 7.5% at screening
- Take pills or basal insulin to manage your blood glucose levels. (unable to participate if on fast acting/meal time insulin)
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.